115 related articles for article (PubMed ID: 21207414)
1. Expression of p-JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia.
Ikezoe T; Kojima S; Furihata M; Yang J; Nishioka C; Takeuchi A; Isaka M; Koeffler HP; Yokoyama A
Int J Cancer; 2011 Nov; 129(10):2512-21. PubMed ID: 21207414
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of signal transducer and activator of transcription 5 by the inhibitor of janus kinases stimulates dormant human leukemia CD34+ /CD38- cells and sensitizes them to antileukemia agents.
Ikezoe T; Yang J; Nishioka C; Kojima S; Takeuchi A; Phillip Koeffler H; Yokoyama A
Int J Cancer; 2011 May; 128(10):2317-25. PubMed ID: 21128225
[TBL] [Abstract][Full Text] [Related]
3. AZ960, a novel Jak2 inhibitor, induces growth arrest and apoptosis in adult T-cell leukemia cells.
Yang J; Ikezoe T; Nishioka C; Furihata M; Yokoyama A
Mol Cancer Ther; 2010 Dec; 9(12):3386-95. PubMed ID: 21159615
[TBL] [Abstract][Full Text] [Related]
4. Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2.
Gozgit JM; Bebernitz G; Patil P; Ye M; Parmentier J; Wu J; Su N; Wang T; Ioannidis S; Davies A; Huszar D; Zinda M
J Biol Chem; 2008 Nov; 283(47):32334-43. PubMed ID: 18775810
[TBL] [Abstract][Full Text] [Related]
5. IL-1β inhibits self-renewal capacity of dormant CD34⁺/CD38⁻ acute myelogenous leukemia cells in vitro and in vivo.
Yang J; Ikezoe T; Nishioka C; Nobumoto A; Yokoyama A
Int J Cancer; 2013 Oct; 133(8):1967-81. PubMed ID: 23564444
[TBL] [Abstract][Full Text] [Related]
6. Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells.
Tong H; Ren Y; Zhang F; Jin J
Eur J Haematol; 2008 Oct; 81(4):259-66. PubMed ID: 18616510
[TBL] [Abstract][Full Text] [Related]
7. WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells.
Ferrajoli A; Faderl S; Van Q; Koch P; Harris D; Liu Z; Hazan-Halevy I; Wang Y; Kantarjian HM; Priebe W; Estrov Z
Cancer Res; 2007 Dec; 67(23):11291-9. PubMed ID: 18056455
[TBL] [Abstract][Full Text] [Related]
8. Chemosensitivity of nonleukemic clonogenic precursors in AML patients in complete remission: association with CD34(+) mobilization and with disease-free survival.
Milone G; Avola G; Leotta S; Strano A; Camuglia MG; Pinto V; Mercurio S; Poidomani M; Coppoletta S; Di Marco AL; Consoli C; Triolo A; Spadaro A; Privitera A; Ragusa A; Tibullo D; Di Mercurio S
Exp Hematol; 2012 Jan; 40(1):35-47.e2. PubMed ID: 22019627
[TBL] [Abstract][Full Text] [Related]
9. microRNA-146a Promotes Growth of Acute Leukemia Cells by Downregulating Ciliary Neurotrophic Factor Receptor and Activating JAK2/STAT3 Signaling.
Wang L; Zhang H; Lei D
Yonsei Med J; 2019 Oct; 60(10):924-934. PubMed ID: 31538427
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of c-kit and JAK2 gene mutations in t(8;21) acute myeloid leukemia].
Li WY; Sun AN; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2008 Dec; 29(12):797-801. PubMed ID: 19176031
[TBL] [Abstract][Full Text] [Related]
11. Wogonoside impedes the progression of acute myeloid leukemia through inhibiting bone marrow angiogenesis.
Lin B; Zhao K; Yang D; Bai D; Liao Y; Zhou Y; Yu Z; Yu X; Guo Q; Lu N
J Cell Physiol; 2019 Feb; 234(2):1913-1924. PubMed ID: 30105796
[TBL] [Abstract][Full Text] [Related]
12. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
[TBL] [Abstract][Full Text] [Related]
13. Bim and Mcl-1 exert key roles in regulating JAK2V617F cell survival.
Rubert J; Qian Z; Andraos R; Guthy DA; Radimerski T
BMC Cancer; 2011 Jan; 11():24. PubMed ID: 21247487
[TBL] [Abstract][Full Text] [Related]
14. Deregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia.
Del Poeta G; Bruno A; Del Principe MI; Venditti A; Maurillo L; Buccisano F; Stasi R; Neri B; Luciano F; Siniscalchi A; de Fabritiis P; Amadori S
Curr Cancer Drug Targets; 2008 May; 8(3):207-22. PubMed ID: 18473734
[TBL] [Abstract][Full Text] [Related]
15. Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML).
Del Poeta G; Venditti A; Del Principe MI; Maurillo L; Buccisano F; Tamburini A; Cox MC; Franchi A; Bruno A; Mazzone C; Panetta P; Suppo G; Masi M; Amadori S
Blood; 2003 Mar; 101(6):2125-31. PubMed ID: 12424199
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of B7-H3 augments anti-apoptosis of colorectal cancer cells by Jak2-STAT3.
Zhang T; Jiang B; Zou ST; Liu F; Hua D
World J Gastroenterol; 2015 Feb; 21(6):1804-13. PubMed ID: 25684945
[TBL] [Abstract][Full Text] [Related]
17. [Prognostic factor analysis of 77 old patients with acute myelogenous leukemia].
Shao B; Gao YR; Wang C; Yan SK; Cai Q; Jiang JL; Yang J; Bai HT; Zhao M; Zhao CX
Ai Zheng; 2006 Aug; 25(8):1007-12. PubMed ID: 16965684
[TBL] [Abstract][Full Text] [Related]
18. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
19. Functional expression of Fas (CD95) in acute myeloid leukemia cells in the context of CD34 and CD38 expression: possible correlation with sensitivity to chemotherapy.
Iijima N; Miyamura K; Itou T; Tanimoto M; Sobue R; Saito H
Blood; 1997 Dec; 90(12):4901-9. PubMed ID: 9389707
[TBL] [Abstract][Full Text] [Related]
20. Bcl-2 protein expression in normal human bone marrow precursors and in acute myelogenous leukemia.
Porwit-MacDonald A; Ivory K; Wilkinson S; Wheatley K; Wong L; Janossy G
Leukemia; 1995 Jul; 9(7):1191-8. PubMed ID: 7543174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
